NovaBridge Biosciences (NBP) vs Upstream Bio (UPB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
NovaBridge Biosciences (NBP) has outperformed Upstream Bio (UPB) over the past year, losing 78.2% versus a loss of 86.8%. Upstream Bio is the larger company by market cap ($151.2 million vs $146.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NBP | UPB |
|---|---|---|
| Share price | $1.26 | $2.76 |
| Market cap | $146.16M | $151.17M |
| 1-day change | -2.33% | -18.10% |
| YTD return | -68.34% | -89.83% |
| 1-year return | -78.16% | -86.84% |
| 5-year return | -98.13% | — |
| EPS (TTM) | $-0.69 | $-2.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $2.85M |
| Revenue growth (YoY) | — | +20.42% |
| Net income (latest FY) | $-46.27M | $-143.44M |
| Operating margin | — | -5618.82% |
| Net margin | — | -5026.03% |
| 52-week high | $5.97 | $33.68 |
| 52-week low | $1.26 | $2.74 |
| Distance from 52-week high | -78.89% | -91.81% |
| Analyst consensus | none | none |
| Avg. price target upside | +614.29% | +1028.26% |
| Average volume | 390.05K | 734.05K |
| Shares outstanding | 116.00M | 54.77M |
| Employees | 30 | 75 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About NovaBridge Biosciences
NBP stock →NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology.
Health Care · Biotechnology: Pharmaceutical Preparations · 30 employees
About Upstream Bio
UPB stock →Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
NBP vs UPB FAQ
Which is bigger, NovaBridge Biosciences or Upstream Bio?
Upstream Bio (UPB) is larger, with a market capitalization of $151.17M compared with $146.16M for NovaBridge Biosciences (NBP).
Which stock has performed better over the past year, NBP or UPB?
NBP returned -78.16% over the past 12 months, compared with -86.84% for UPB (price return, excluding dividends). Past performance does not predict future results.
Are NovaBridge Biosciences and Upstream Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.